BridgeBio Pharma

Quote
























BridgeBio - Sr. Director, Marketing

To learn more about our story and company culture, visit us at https://bridgebio.com

Who You Are

The Senior Director of Marketing will support the development of a late-stage commercial asset, Acoramdis, for ATTR-cardiomyopathy. The Senior Director of Marketing will drive cross-functional collaboration and tactical alignment, ensuring success in the US and across the globe. This individual will lead the development of commercial deliverables, including market development and product adoption. This person will lead a strategic role on commercial product teams, work closely with Market Insights, Development, Regulatory, Medical Affairs, and other key stakeholders, and should feel at home in a fast-paced, ambiguous environment. This position requires excellent communication skills, leadership, and a proven ability to influence the organization. The Senior Director of Marketing will report to the Senior Vice President, Global Marketing.




It looks like BridgeBio / Eidos is finally beginning their TTR build-out.
 
























All cause mortality. p=057. A swing and a miss.

Only meaningful non-surrogate data point they hit on was HF Hospitalization. P<0.001.

Other statistically significant measures were change in 6MWT at 18 months (missed at 9). p<0.001 and change in NT ProBMP p<0.001 (both surrogate endpoints already proven to be meaningful with patty at 12 months).

Primary endpoint was a win loss ratio of a bunch of composite endpoints including those above but not all cause mortality. Good luck getting HCPs to buy into this for anything other than a cheaper stabilizer than taf (if they're smart).

Amvuttra will crush these numbers.
 






Drink that Kool Aid you moron. Learn to understand the data and wait for the total read out. Amvuttra are you kidding me. the study isn't powered, everyone knows it is going to fail.....and your Amvuttra problems are just starting. Dream on foolish one. You ever go to an ASG meeting?
 






anonymous said:
I doubt anyone on the TTR team is polishing up their resume for a stabilizer that failed to show any benefit in 9 months for the same endpoint in Apollo B.
Click to expand...

Anyone with a half a brain understands the drug did not fail, and why the results were what they were. Are you that stupid of a drone? You must have been at Pfizer.
 
























anonymous said:
FDA just gave a middle finger to Alnylam - suck it a-holes. We are coming for ya!
Click to expand...

Please tell us again about your composite endpoint, your inability to demonstrate the same results as us at 9 months and the inability to achieve all cause mortality data. I hope you're cheaper than taf otherwise it's going to be a tough row to hoe for you. But your enthusiasm is cute and admirable.
 




































Top Bottom
Back
Quote